Drugs / TolDCB29
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05251870 | Aug 2021 → Aug 2024 | rheumatoid arthritis | UMC Utrecht | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TolDCB29 | “The investigators hypothesize that dendritic cell therapy with TolDCB29 is safe and induces immune tolerance in rheumatoid arthritis patients.” NCT05251870 ↗ |
| Route | Other | “Intranodal administration into an inguinal lymphnode.” NCT05251870 ↗ |